1900–1925

Early drug development

  DTP EVOLUTION — high bandwidth | low bandwidth | transcript

1926–1950

Mechlorethamine, ethinyl estradiol, TEM, mercaptopurine, methotrexate, busulfan

1955

Mouse L1210 leukemia model, screening of up to 40K per year

Creation of CCNSC

1957

Entering the computer age

1962

Carmustine 409962 received

1967

Chemical Abstracts Service (CAS) contract begins

1968

Geldanamycin 122750 received

1969

Taxol 125973 received

  TAXOL — high bandwidth | low bandwidth | transcript

1970

Multimodal therapy proven more effective than surgery alone in some cancers

1971

War on cancer declared by President Nixon

1975

Mouse P388 model adopted as primary screen

Input at 15,000 per year

Rational selection approach used

1976

Tumor panel experiment

1977

Taxol 125973 presented to DN

1978

Biological Response Modifiers Program planning begins

Average cost of preclinical development is $215,000

200 companies have signed discreet agreement

  CISPLATIN — high bandwidth | low bandwidth | transcript

1979

Linear array becomes standard approach

1980

17-AAG 330507 (Geldanamycin analog) received

Cures against leukemias possible

Lacking effective drugs for solid tumors in general

1981

Hodes model for ranking small molecule structures

1982

Tumor panel adopted

Mix of mouse and human tumors

  TUMOR PANEL — high bandwidth | low bandwidth | transcript

1983

NCDDG Program begins

1984

Taxol 125973 clinical trials begin

DTP produces 1,000,000 injectable units per year

1985

Drug Information System (DIS) developed

Chemical Abstracts Service (CAS) contract ends

1986

Halichondrin B 609395 received

1989

COMPARE paper published

1990

Human tumor cell line assay adopted as primary screen

Depsipeptide 630176 received

Erbitux 632307 NCDDG begins work

1991

Natural products repository makes extracts available to researchers

Depsipeptide 630176 presented to DN

  FLUDARABINE — high bandwidth | low bandwidth | transcript

1992

Human tumor cell line panel revised to include breast and prostate cell lines

Geldanamycin 122750 presented to DN

Flavopiridol 649890 received and presented to DN

Halichondrin B 609395 presented to DN

1994

DTP Website inaugurated

Benzothiazole 674495 parent received

Flavopiridol 649890 clinical trials begin

  FLAVOPIRIDOL 649890 — high bandwidth | low bandwidth | transcript

1995

Hollow fiber assay adopted as prerequisite for xenograft studies

Velcade 681239 received

Biological Resources Branch integrated into DTP

1996

Benzothiazole 674495 parent presented to DN

Aminoflavone 686288 received

Depsipeptide 630176 clinical trials begin

BL22 691237 presented to DN

BCNU 409962 (Gliadel Wafer) developed by NCDDG

Yeast screening program begins at Fred Hutchinson Cancer Research Center

1997

SJG-136 694501 received

Velcade 681239 presented to DN

Aminoflavone 686288 presented to DN

17-AAG 330507 presented to DN

1998

RAID Program begins

Mouse Models of Human Cancers Consortium

17-DMAG 707545 (Geldanamycin analog) received

E7389 707389 (Halichondrin B analog) presented to DN

Emphasis on extramural support

"Open" repository of compounds created

Input down to 3K in favor of molecular targets emphasis

1999

Epothilone 703147 RAID project approved

BL22 691237 clinical trial begins

Velcade 681239 clinical trials begin

Benzothiazole prodrug 710305 received

Aminoflavone prodrug 710464 received

SJG-136 694501 presented to DN

17-AAG 330507 clinical trials begin

E7 Vaccine 723254 RAID project approved

2000

Dynamic Molecular Targets Website launched, including first microarray data

Decision Network (DN) changed to Drug Development Group (DDG)

2001

Epothilone 703147 clinical trials begin

Screening of 140,000 compounds in yeast screen completed

R*A*N*D and IIP initiatives begin

2002

Phortress 710305 (Benzothiazole prodrug) presented to DDG

17-DMAG 707545 presented to DDG

E7389 707389 clinical trials begin

Aminoflavone prodrug 710464 presented to DDG

2003

Type 1 diabetes RAID begins

SJG-136 694501 clinical trials begin

Velcade 681239 receives NDA for multiple myeloma

Phortress 710305 in clinical trials in the United Kingdom

E7 Vaccine 723254 clinical trials begin

2004

Academic Public Private Partnership Program (AP4) planning grants funded

17-DMAG 707545 clinical trials begin

2005

NIH RAID begins

Aminoflavone prodrug 710464 clinical trials begin

DTP's 50th anniversary

2006

Reinventing drug development at NCI: PK/PD

2015

  FUTURE OF DTP — high bandwidth | low bandwidth | transcript

  NCI CHALLENGE GOAL — high bandwidth | low bandwidth | transcript

 

 


FDA-Approved Drugs DTP Home Cancer.gov National Institutes of Health National Cancer Institute Department of Health and Human Services National Institutes of Heatlh FirstGov